Literature DB >> 14673528

CC chemokine receptor 5 delta32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia.

Hermann E Wasmuth1, Alexa Werth, Tobias Mueller, Thomas Berg, Christoph G Dietrich, Andreas Geier, Ramin Schirin-Sokhan, Carsten Gartung, Johann Lorenzen, Siegfried Matern, Frank Lammert.   

Abstract

Recently CC chemokine receptor 5 (CCR5) related immune mechanisms and a functional mutation of the CCR5 gene have been implicated in hepatitis C virus (HCV) infection in a cohort of predominantly hemophiliac patients. The present study investigated the frequency and clinical consequences of the CCR5 Delta32 mutation in two genetically homogeneous populations of HCV infected patients with a different risk profile for infection. Genomic DNA samples from 333 German patients with chronic HCV infection were screened by PCR for the presence of the CCR5 Delta32 polymorphism. In-hospital patients admitted for other diseases than viral hepatitis but with a comparable risk for HCV exposure were used as control population ( n=125). Allele frequencies of CCR5 Delta32 polymorphism did not differ significantly between the two groups (7.6% and 9.5%, respectively) and control subjects (10.4%), and did not deviate from Hardy-Weinberg equilibrium in any group. Furthermore, there were no major differences between patients with respect to HCV genotypes, viral loads, liver enzymes, or fibrosis scores in relation to the presence or absence of the heterozygous CCR5 Delta32 mutation. Differences in inflammatory scores in liver biopsy samples and response to antiviral therapy in CCR5 Delta32 heterozygotes in one cohort could neither be reproduced in the other group of patients nor when both cohorts were pooled. These results argue against a strong effect of the CCR5 Delta32 deletion regarding these phenotypes. In conclusion, we found no increased frequency of the CCR5 Delta32 polymorphism in two independent cohorts of patients with HCV infection but without hemophilia as the main risk factor for infection. As the major difference to investigations demonstrating an association between CCR5 Delta32 and HCV infection is the selection of cases and controls, our study emphasizes the importance of epidemiological criteria for association studies of HCV infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14673528     DOI: 10.1007/s00109-003-0505-0

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  25 in total

1.  Linkage of the CCR5 Delta 32 mutation with a functional polymorphism of CD45RA.

Authors:  H X Liao; D C Montefiori; D D Patel; D M Lee; W K Scott; M Pericak-Vance; B F Haynes
Journal:  J Immunol       Date:  2000-07-01       Impact factor: 5.422

2.  Bias and causal associations in observational research.

Authors:  David A Grimes; Kenneth F Schulz
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

Review 3.  Population stratification and spurious allelic association.

Authors:  Lon R Cardon; Lyle J Palmer
Journal:  Lancet       Date:  2003-02-15       Impact factor: 79.321

4.  Distribution of the CCR5 gene 32-bp deletion in Europe.

Authors:  G Lucotte; G Mercier
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-10-01

Review 5.  Chemokines--chemotactic cytokines that mediate inflammation.

Authors:  A D Luster
Journal:  N Engl J Med       Date:  1998-02-12       Impact factor: 91.245

6.  CC chemokine receptor 5 and interleukin-1 receptor antagonist gene polymorphisms in patients with primary Sjögren's syndrome.

Authors:  M Petrek; Z Cermáková; B Hutyrová; D Miceková; J Drábek; J Rovensky; V Bosák
Journal:  Clin Exp Rheumatol       Date:  2002 Sep-Oct       Impact factor: 4.473

7.  Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver.

Authors:  P L Shields; C M Morland; M Salmon; S Qin; S G Hubscher; D H Adams
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

8.  Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.

Authors:  M Samson; F Libert; B J Doranz; J Rucker; C Liesnard; C M Farber; S Saragosti; C Lapoumeroulie; J Cognaux; C Forceille; G Muyldermans; C Verhofstede; G Burtonboy; M Georges; T Imai; S Rana; Y Yi; R J Smyth; R G Collman; R W Doms; G Vassart; M Parmentier
Journal:  Nature       Date:  1996-08-22       Impact factor: 49.962

9.  Effects of the CCR5-Delta32 mutation on antiviral treatment in chronic hepatitis C.

Authors:  Golo Ahlenstiel; Thomas Berg; Rainer P Woitas; Frank Grünhage; Agathe Iwan; Lothar Hess; Hans H Brackmann; Bernd Kupfer; Andrea Schernick; Tilman Sauerbruch; Ulrich Spengler
Journal:  J Hepatol       Date:  2003-08       Impact factor: 25.083

10.  Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T lymphocytes from patients with chronic hepatitis C infection.

Authors:  Mathias Lichterfeld; Ludger Leifeld; Hans Dieter Nischalke; Jürgen K Rockstroh; Lothar Hess; Tilman Sauerbruch; Ulrich Spengler
Journal:  J Infect Dis       Date:  2002-05-20       Impact factor: 5.226

View more
  10 in total

1.  CCR5Delta32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C.

Authors:  Ankur Goyal; P V Suneetha; G T Kumar; Deepak K Shukla; Naveen Arora; Shiv K Sarin
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

2.  A DDX5 S480A polymorphism is associated with increased transcription of fibrogenic genes in hepatic stellate cells.

Authors:  Jinsheng Guo; Feng Hong; Johnny Loke; Steven Yea; Chooi Ling Lim; Ursula Lee; Derek A Mann; Martin J Walsh; John J Sninsky; Scott L Friedman
Journal:  J Biol Chem       Date:  2009-12-17       Impact factor: 5.157

Review 3.  Evolving challenges in hepatic fibrosis.

Authors:  Scott L Friedman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06-29       Impact factor: 46.802

Review 4.  Chemokines in the immunopathogenesis of hepatitis C infection.

Authors:  Mathis Heydtmann; David H Adams
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

5.  CCR1 and CCR5 promote hepatic fibrosis in mice.

Authors:  Ekihiro Seki; Samuele De Minicis; Geum-Youn Gwak; Johannes Kluwe; Sayaka Inokuchi; Christina A Bursill; Josep M Llovet; David A Brenner; Robert F Schwabe
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

6.  Frequency of CCR5Δ32 allele in healthy Bosniak population.

Authors:  Grażyna Adler; Amina Valjevac; Karolina Skonieczna-Żydecka; Mirela Mackic-Djurovic; Miłosz Parczewski; Anna Urbańska; Nermin Nusret Salkic
Journal:  Bosn J Basic Med Sci       Date:  2014-08-28       Impact factor: 3.363

Review 7.  Recognition of genetic factors influencing the progression of hepatitis C : potential for personalized therapy.

Authors:  Julie R Jonsson; David M Purdie; Andrew D Clouston; Elizabeth E Powell
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 8.  The role of CCR5 in HCV infection.

Authors:  Martin Coenen; Jacob Nattermann
Journal:  Eur J Med Res       Date:  2010-03-30       Impact factor: 2.175

Review 9.  Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases.

Authors:  Joel Henrique Ellwanger; Bruna Kulmann-Leal; Valéria de Lima Kaminski; Andressa Gonçalves Rodrigues; Marcelo Alves de Souza Bragatte; José Artur Bogo Chies
Journal:  Virus Res       Date:  2020-05-30       Impact factor: 3.303

10.  CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro.

Authors:  Jason T Blackard; Ling Kong; Susan D Rouster; Rebekah Karns; Paul S Horn; Shyam Kottilil; M Tarek Shata; Kenneth E Sherman
Journal:  PLoS One       Date:  2019-10-29       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.